Pharmacology

Pharmacology

Understand the complex mechanisms of how drugs work to give therapeutic benefit, and the importance of understanding side effects and interactions.
 
Research Methods in Pharmacology
1. Research Methods in Pharmacology
  • Evidence-based medicine and the three components: evidence, expertise, patient preference.
  • The hierarchy of evidence, from systematic reviews (studies that gather and combine all the trials on one question) of randomised controlled trials (RCTs) down to expert opinion. Higher levels are less likely to be biased.
  • Statistical interpretation. P values (how likely a result at least this extreme would be if there were no real effect). Confidence intervals (the range in which the true effect probably lies). Forest plots (charts that show the results of several trials side by side). NNT and NNH (number needed to treat or to harm: how many patients must be treated for one to benefit or be harmed).
  • Phases I–IV of drug development and the role of post-marketing surveillance (monitoring a drug for harms after it has been licensed).
Pharmacokinetics
2. Pharmacokinetics
  • What the body does to the drug: absorption, distribution, metabolism, excretion (ADME).
  • Bioavailability (the fraction of a dose that reaches the blood). Volume of distribution (how widely a drug spreads through the body compared with staying in the blood). Clearance (the volume of blood cleared of the drug in a given time). Half-life (the time for the drug level to fall by half). Together these decide how much drug to give and how often.
  • First-order (a fixed proportion of the drug removed in each unit of time) vs zero-order (a fixed amount removed in each unit of time) elimination kinetics, with worked examples.
  • Steady state (the point where the amount of drug going in equals the amount going out) and loading doses (a larger first dose, given to reach the target level quickly). The rule is that steady state is reached after about 5 half-lives.
Pharmacodynamics
3. Pharmacodynamics
  • What the drug does to the body: receptors, enzymes, channels and transporters.
  • Affinity (how tightly a drug binds to its receptor), efficacy and potency on the dose–response curve (a graph of how the effect changes as the dose increases).
  • Full and partial agonists, antagonists and inverse agonists (drugs that reduce a receptor's activity even when no agonist is present).
  • Competitive vs non-competitive antagonism (more agonist can overcome a competitive antagonist, but not a non-competitive one), and the therapeutic index (the gap between the effective dose and the toxic dose).
Pharmacovigilance and Pharmacogenetics
4. Pharmacovigilance and Pharmacogenetics
  • Adverse drug reactions: Type A (predictable and dose-related) and Type B (unpredictable), and the DoTS classification (dose-relatedness, time course and susceptibility).
  • The Yellow Card scheme (the UK system for reporting suspected side effects of medicines) and the role of the Medicines and Healthcare products Regulatory Agency (MHRA) in UK drug safety.
  • Pharmacogenetic variants (inherited gene differences that change how a person responds to a drug) that matter in prescribing. TPMT: thiopurine methyltransferase, an enzyme that breaks down thiopurines such as azathioprine. HLA-B*5701: a human leukocyte antigen (HLA) variant linked to serious reactions to abacavir. HLA-B*1502: an HLA variant linked to severe skin reactions to carbamazepine. CYP2D6: a liver enzyme that turns codeine into morphine. DPYD: the gene for dihydropyrimidine dehydrogenase (DPD), the enzyme that breaks down fluorouracil and related drugs.
  • Drugs for which a test is advised before prescribing in UK practice. Abacavir: test for the HLA-B*5701 variant. Carbamazepine: test for the HLA-B*1502 variant in people of Han Chinese or Thai origin. Fluorouracil, capecitabine and tegafur: test for DPD deficiency, which raises the risk of severe toxicity. Genotyping means testing a patient's DNA for a gene variant.
Safe Prescribing
5. Safe Prescribing
  • The principles of safe prescribing: indication, contraindications, interactions, monitoring.
  • Common high-risk prescribing errors and how electronic prescribing reduces them.
  • Prescribing in pregnancy, paediatrics, the elderly, and renal/hepatic impairment.
  • Daily-use resources: the British National Formulary (BNF) and BNF for Children (BNFc), NICE guidance, TOXBASE (the UK online poisons database) and STOPP/START criteria (checklists for spotting potentially inappropriate and potentially missing prescriptions in older adults).
Cholinergic Pharmacology

6. Cholinergic Pharmacology

  • Locate the cholinergic synapse (a junction where acetylcholine passes a signal on), identify nicotinic and muscarinic receptors (the two types of acetylcholine receptor), then predict agonist, inhibitor and antagonist effects.
Adrenergic Pharmacology

7. Adrenergic Pharmacology

  • Map catecholamine (adrenaline, noradrenaline and dopamine) handling and adrenergic receptors (the receptors that respond to adrenaline and noradrenaline) to organ effects, selectivity, reflex responses and direct or indirect drug action.
Hypertension and Heart Failure
8. Hypertension and Heart Failure
  • Definition and stages of hypertension (NICE guideline NG136). The ACD pathway: A is an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), C is a calcium-channel blocker and D is a thiazide-like diuretic (a diuretic such as indapamide).
  • The renin–angiotensin–aldosterone system (the hormone system that raises blood pressure and makes the kidneys keep salt and water) and the drugs that block it.
  • HFrEF disease-modifying therapy: ACE inhibitor/ARB, beta-blocker, MRA, SGLT2 inhibitor.
  • Acute decompensated heart failure (a sudden worsening of heart failure): diuretics, vasodilators (drugs that widen blood vessels) and inotropes (drugs that make the heart contract harder).
Cardiac Arrhythmias
9. Cardiac Arrhythmias
  • The fast (working myocyte, an ordinary pumping heart muscle cell) and slow (sinoatrial and atrioventricular nodes, which set and pass on the heart rhythm) cardiac action potentials.
  • The Vaughan-Williams classification (the system that groups antiarrhythmic drugs, which treat abnormal heart rhythms, into classes by how they act).
  • NICE-aligned management of atrial fibrillation (an irregular, often fast heart rhythm that starts in the upper chambers): rate, rhythm and stroke risk.
  • Drugs that prolong the QT interval (the part of the ECG that shows the heart recovering between beats) and torsades de pointes (a dangerous fast heart rhythm that can follow a long QT interval).
Antiplatelets, Anticoagulants and Thrombolysis
10. Antiplatelets, Anticoagulants and Thrombolysis
  • Antiplatelets (drugs that stop platelets sticking together): aspirin, clopidogrel, ticagrelor, prasugrel, and the glycoprotein IIb/IIIa inhibitors (drugs that block the receptor platelets use to clump together) abciximab, eptifibatide and tirofiban (specialist use only).
  • Anticoagulants: warfarin, direct oral anticoagulants (DOACs), heparin and low molecular weight heparin (LMWH). The -xabans, such as apixaban, are DOACs that block factor Xa (a clotting protein). Dabigatran is a DOAC that blocks thrombin (another clotting protein).
  • Thrombolysis (using drugs to break down a clot that is blocking a blood vessel): alteplase or tenecteplase in acute ischaemic stroke.
  • Thrombolysis in STEMI (ST-elevation myocardial infarction, a type of heart attack) when primary PCI (percutaneous coronary intervention: emergency opening of the blocked artery with a balloon and stent) cannot be delivered within 120 minutes. The 120 minutes are counted from the time when thrombolysis could first have been given.
  • Major bleeding management and reversal agents (drugs that cancel the effect of a blood thinner).
Hyperlipidaemias
11. Hyperlipidaemias
  • Lipid metabolism, LDL and the pathology of atherogenesis (how fatty plaques form in artery walls).
  • Statins (drugs that lower cholesterol by blocking its production in the liver) for primary and secondary prevention (preventing a first and a repeat cardiovascular event), with NICE thresholds (the risk levels at which treatment is recommended).
  • Ezetimibe, PCSK9 inhibitors and bempedoic acid: other cholesterol-lowering drugs, mostly added to a statin. Ezetimibe, alone or with bempedoic acid, is also used when statins are contraindicated or not tolerated.
  • Statin-related myopathy (muscle pain and weakness from muscle damage), hepatotoxicity (liver damage caused by a drug) and other adverse effects.
Diuretics and Renal Pharmacology
12. Diuretics and Renal Pharmacology
  • The site of action of each diuretic class along the nephron.
  • Loop diuretics (acting on the loop of Henle, the hairpin-shaped part of the kidney tubule); thiazide diuretics (acting on the early distal tubule, the part just after the loop); potassium-sparing diuretics (acting on the collecting duct to keep potassium in the body); osmotic diuretics (which draw water into the urine); and carbonic anhydrase inhibitors (such as acetazolamide, which act on the proximal tubule, the first part of the tubule).
  • ADH (antidiuretic hormone) V2 receptor antagonists, and SGLT2 inhibitors (which are not classed as diuretics, but increase urinary glucose excretion and can cause volume depletion, meaning loss of body fluid).
  • Electrolyte disturbances and clinical pitfalls of diuretic therapy.
Pharmacology of Insulin
13. Pharmacology of Insulin
  • Glucose-stimulated insulin release from the pancreatic beta-cell.
  • Rapid, short, intermediate and long-acting insulin preparations (the different types of insulin) and regimens (the schedules for giving them).
  • Non-insulin therapies in type 2 diabetes: metformin; SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors); glucagon-like peptide-1 (GLP-1) receptor agonists and tirzepatide (drugs that copy gut hormones called incretins); DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors, which slow the breakdown of those hormones); sulfonylureas (drugs that make the pancreas release more insulin); and pioglitazone (a drug that makes tissues more sensitive to insulin).
  • Recognition and management of hypoglycaemia (dangerously low blood glucose) and diabetic ketoacidosis (DKA: a dangerous build-up of ketones, which are acids, when the body has too little insulin).
Reproductive and Post-reproductive Health
14. Reproductive and Post-reproductive Health
  • Combined (oestrogen and progestogen) and progestogen-only (containing only a progesterone-like hormone) hormonal contraception.
  • Hormone replacement therapy (HRT) regimens and the balance of benefit against the risks of breast cancer and venous thromboembolism (VTE: a blood clot in a vein). These risks differ with the type and route of HRT.
  • Drugs used in fertility, labour, and post-partum haemorrhage (heavy bleeding after childbirth).
  • MHRA restrictions on valproate (an antiseizure medicine that can harm an unborn baby). These include the Pregnancy Prevention Programme for women and girls who could become pregnant. They also include the 2024 rule that nobody under 55 starts valproate for the first time unless two specialists agree. Learn how to prescribe to reduce the risk of harm in pregnancy.
Antibiotics
15. Antibiotics
  • Antibiotic classes mapped to their bacterial targets (cell wall, ribosome, DNA, folate).
  • Empirical therapy (treatment started before the exact germ is known) for common UK infections per NICE.
  • Mechanisms and prevention of antimicrobial resistance (germs no longer being killed by the drugs that used to work).
  • High-risk drugs: aminoglycosides, vancomycin and fluoroquinolones (antibiotics that need extra care in prescribing and monitoring).
Antivirals
16. Antivirals
  • Antiretrovirals (drugs that act against retroviruses such as HIV) and HIV combination regimens (several drugs taken together).
  • Drugs for herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), hepatitis B and C, and influenza.
  • Post-exposure prophylaxis (drugs taken soon after a risk event to stop infection) and pre-exposure prophylaxis (drugs taken beforehand by people at risk).
  • Nephrotoxic (harmful to the kidneys) and bone-marrow-suppressing antivirals.
Cancer Chemotherapy
17. Cancer Chemotherapy
  • The cell cycle and cytotoxic (cell-killing) mechanisms of action.
  • Cytotoxic, hormonal, targeted and immunotherapy (using the immune system to attack cancer) approaches.
  • Common chemotherapy toxicities and oncological emergencies (neutropenic sepsis: infection in a patient with very few neutrophils, the white cells that fight bacteria; tumour lysis: a surge of chemicals released when many cancer cells die at once).
  • Biologic therapies (drugs made from living cells, such as antibodies) and immune checkpoint inhibitors (drugs that release the brakes on immune cells so that they attack cancer).
Anaesthetics
18. Anaesthetics
  • General anaesthetic induction (starting anaesthesia), maintenance (keeping the patient anaesthetised) and adjunct agents (extra drugs given alongside, such as painkillers).
  • Local anaesthetics: potency, duration and systemic toxicity.
  • Neuromuscular blockers (muscle relaxants used during surgery) and reversal agents (drugs that cancel their effect).
  • Malignant hyperthermia (a rare, life-threatening reaction to some anaesthetic drugs, causing a very high temperature and rigid muscles) and local anaesthetic systemic toxicity (LAST).
Opioids
19. Opioids
  • The WHO analgesic ladder (a stepwise guide to pain relief, from non-opioid painkillers to weak and then strong opioids), which is no longer recommended as a strict protocol for cancer pain.
  • Weak and strong opioids (painkillers related to morphine): pharmacokinetics and indications.
  • Opioid toxicity and reversal with naloxone (a drug that quickly reverses the effects of opioids).
  • Safe opioid prescribing in palliative care: NICE recommends regular oral morphine when starting a strong opioid in advanced and progressive disease. Safe opioid prescribing in chronic pain: NICE advises against starting opioids for chronic primary pain (pain with no clear underlying condition).
Introduction to Psychopharmacology

20. Introduction to Psychopharmacology

  • Link monoamine (such as serotonin, noradrenaline and dopamine) and GABA (gamma-aminobutyric acid, the brain's main inhibitory chemical) signalling to the mechanisms of the major psychotropic drugs (drugs that act on mood, thinking or behaviour). Understand the delay before benefit while the brain adapts, adverse effects and withdrawal.
Epilepsy and Anti-epileptic Drugs
21. Epilepsy and Anti-epileptic Drugs
  • Seizure classification (sorting seizures by where they start and how they look) and first-line antiseizure medication (the drugs tried first, also called antiepileptic drugs, AEDs) per NICE.
  • Four commonly used antiseizure drugs: lamotrigine, levetiracetam, sodium valproate and carbamazepine.
  • Management of status epilepticus (convulsive seizures, which cause shaking movements, lasting 5 minutes or more).
  • MHRA valproate restrictions. The Pregnancy Prevention Programme applies to women and girls who could become pregnant. Nobody (male or female) under 55 starts valproate for the first time unless two specialists agree.
Parkinson's Disease and Myasthenia Gravis
22. Parkinson's Disease and Myasthenia Gravis
  • Dopaminergic therapy (treatment that boosts dopamine): levodopa (a drug the brain turns into dopamine), dopamine agonists, and monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) inhibitors, which slow the breakdown of dopamine and levodopa.
  • Acetylcholinesterase inhibitors (drugs that stop the breakdown of acetylcholine) in myasthenia gravis (an autoimmune disease that causes weak muscles).
  • Cholinergic and myasthenic crises (a sudden, severe worsening of muscle weakness, which can affect breathing).
  • Botulinum toxin (a toxin that relaxes muscles when injected) and other add-on neurological therapies.
NSAIDs
23. NSAIDs
  • The arachidonic acid pathway (the chain of reactions that makes prostaglandins and related chemicals; prostaglandins are chemical messengers that cause pain, fever and inflammation) and COX-1/COX-2 isoforms (two forms of the cyclo-oxygenase enzyme).
  • Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and the COX-2-selective coxibs (drugs that mainly block COX-2).
  • Gastrointestinal, renal and cardiovascular adverse effects of NSAIDs.
  • Corticosteroid pharmacology and cushingoid effects (features like those of Cushing's syndrome, such as a round face, weight gain and thin skin).
Immunosuppression and Disease-modifying Therapy
24. Immunosuppression and Disease-modifying Therapy
  • Corticosteroid, calcineurin inhibitor (a drug that blocks T-cell activation) and antimetabolite (a drug that blocks cell division by interfering with DNA building blocks) immunosuppressants.
  • Conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (an autoimmune disease that causes painful, swollen joints).
  • Immunosuppression regimens for solid-organ transplants (such as kidney or liver transplants).
  • Infection risk and safe monitoring of immunosuppressed patients.
Pharmacology of Airway Control
25. Pharmacology of Airway Control
  • NICE 2024 (NG245) stepwise pathway for asthma.
  • Short-acting beta-2 agonists (SABAs), long-acting beta-2 agonists (LABAs), inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMAs), leukotriene receptor antagonists (LTRAs) and biologics.
  • Pharmacology of chronic obstructive pulmonary disease (COPD): LAMA+LABA, or LABA+ICS where there are asthmatic features. Inhaled triple therapy (LAMA+LABA+ICS) is considered later, for example after a severe exacerbation (a flare-up needing admission to hospital) or two moderate exacerbations in a year.
  • Acute severe asthma: features and emergency management.
Drugs Affecting Acid Secretion
26. Drugs Affecting Acid Secretion
  • Parietal cell (the stomach cell that makes acid) physiology and the H+/K+ ATPase (the proton pump, which moves hydrogen ions into the stomach).
  • Proton pump inhibitors (PPIs: drugs that stop the stomach making acid) and H2 receptor antagonists (drugs that reduce acid by blocking histamine H2 receptors on the acid-making cells).
  • Helicobacter pylori (a stomach bacterium that causes ulcers) eradication regimens (drug combinations that clear the infection).
  • Risks of long-term PPI use.
Antiemetics and Laxatives
27. Antiemetics and Laxatives
  • The four inputs to the vomiting centre (the brainstem area that triggers vomiting) and their receptors.
  • Choice of antiemetic (anti-sickness drug) by underlying cause.
  • Bulk-forming (adds bulk to the stool), osmotic (draws water into the bowel), stimulant (makes the bowel contract) and softening (softens the stool) laxatives.
  • Pharmacological management of inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Poisoning and STOPP/START
28. Poisoning and STOPP/START
  • Common poisoning syndromes and their specific antidotes (drugs that cancel the effects of a poison).
  • Management of paracetamol, opioid, benzodiazepine (a sedative drug such as diazepam) and tricyclic antidepressant (TCA) overdose.
  • TOXBASE and the National Poisons Information Service (the UK service that gives expert advice on poisoning).
  • STOPP/START criteria in older adults.
Finished here? Check out our other subjects!